Showing results (1-10 of 237) with videos related to
Sort By:
Pageof 24
Recenti Progressi in Medicina|May 12, 2017
Biosimilars in oncology: everybody agrees but nobody uses?Bishal GyawaliJournal of the National Cancer Institute|November 8, 2025
De-escalation trials do not always need to be non-inferiority- A case for superiority design de-escalation trials in oncologyBishal GyawaliEcancermedicalscience|April 8, 2017
Low-value practices in oncology contributing to financial toxicityBishal GyawaliEuropean Journal of Cancer (Oxford, England : 1990)|October 8, 2023
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?Mark J Ratain, Garth W StrohbehnClinical and Translational Science|August 26, 2025
Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling AuthorityMark J Ratain, Garth W StrohbehnEcancermedicalscience|May 11, 2018
Cancer treatment in the last 6 months of life: when inaction can outperform actionBishal Gyawali, Saroj NiraulaAMA Journal of Ethics|February 13, 2020
When Is a Suboptimal Approach to Cancer Screening Better Than None?Ramy Sedhom, Bishal GyawaliCancer Treatment Reviews|September 2, 2017
Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trialsBishal Gyawali, Saroj NiraulaNature Reviews. Clinical Oncology|November 29, 2017
Me too-drugs with limited benefits - the tale of regorafenib for HCCBishal Gyawali, Vinay PrasadPageof 24